Вплив ожиріння на еректильну функцію у чоловіків

Obesity is a chronic disease that is associated with the risk of developing various comorbid pathologies. Patients with metabolic syndrome and obesity have a 2.6-fold increased risk of erectile dysfunction (ED) compared to the general population. The objective: to determine the frequency of detection of ED and the effect of incretins and their relationship with the development of ED in men with obesity and a body mass index (BMI) of 30–34.9 kg/m2. 31 obese patients were included in the study, 29% of them had type 2 diabetes mellitus, 19.4% had prediabetes. The average age of patients was 46.19 ± 2.12 years, BMI – 36.37 ± 1.42 kg/m2. All men were divided into two groups with BMI 30–34.9 kg/m2 (23 men) and BMI > 40 kg/m2 (8 men). The concentration of ghrelin, glucagon-like peptide-1 (GLP-1), thyroid-stimulating hormone, insulin, vitamin D and total testosterone, НOMA index, fasting blood glucose, glycated hemoglobin, total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides were determined in all patients on an empty stomach. Erectile function was assessed using the International Index of Erectile Function (IIEF) questionnaire. Statistical processing of the research results was carried out using IBM SPSS Statistics version 25 for Windows. In the group of patients with a BMI of 30–34.9 kg/m2, 30.4% had normal erectile function, 34.8% had mild ED, 21.7% had moderate ED, 13% had severe ED. Negative correlation was found between the total score of the IIEF questionnaire and age – B = –0.96; 95% confidence interval (CI) [–1.59; –0.32], p = 0.005, and the level of GLP-1 after 60 minutes after meal – B = –0.2; 95% CI [–0.37; –0.026], p = 0.026. Conclusions. Negative relationship between the total score IIEF and age, the level of GLP-1 60 minutes after a meal was founded in obesity patients with BMI 30–34.9 kg/m2, which can lead to a worsening insulin resistance, the progression of obesity, which makes it difficult to achieve therapeutic goals in the treatment of ED.